For Immediate Release
Chicago, IL – May 11, 2010 – Today, Zacks Equity Research discusses the Medical Devices Industry, including Medtronic, Inc. (MDT), Haemonetics Corporation (HAE), Boston Scientific Corporation (BSX), St. Jude Medical Inc. (STJ) and Becton, Dickinson and Company (BDX).
A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/34019/Medical+Devices+Stock+Review+-+May+2010.
We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles.
Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy.
We advise investors to avoid companies that have grown historically through acquisitions. These companies may find it difficult to fund acquisitions in the future. Also, they face increasing challenges in delivering operational synergies from these acquisitions, which are considered to be the prime reason for failures of mergers & acquisitions. Additionally, the financial statements of these companies have a large number of one-time items that affect the quality of earnings.
In our portfolio, we see growth potential in companies dealing with cardiovascular devices, Neuro, blood-related and disposable products. Names in this list include Medtronic, Inc. (MDT), Haemonetics Corporation (HAE), Boston Scientific Corporation (BSX), St. Jude Medical Inc. (STJ) and Becton, Dickinson and Company (BDX). These are all producers of life-sustaining products and are less affected by economic turbulence. Among these names, Medtronic has a diversified presence in Cardiovascular, Neuro, Spinal, Diabetes, ENT, etc.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5510.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5511.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
